Oxycodone Hydrochloride: Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
Sufentanil Citrate: Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
Study summary
We design this randomized controlled trial to compare the safety and efficacy of Oxycodone and Sufentanil for postoperative patient-controlled analgesia in patients undergoing hip surgery, with a view to finding the optimal postoperative analgesic regime with fewer adverse reactions and promoting patients' rehabilitation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria:
* Patients undergoing unilateral hip surgery, sign the "informed consent form".
* Age above 18 years old, with both genders.
Exclusion criteria:
* Pregnant or lactating women.
* Patient with history of drug abuse, including but not limited to opioids, amphetamines, ketamine, etc.
* Allergic to opioids or any other anesthetic agent.
* History or family history of malignant hyperthermia.
* Have history of nervous system diseases such as peripheral neuropathy, psychiatric mental illness, or postoperative delirium.
* Other conditions that the investigators consider unsuitable for participation in the study, such as Parkinson's disease, unable to communicate, or impairment of cognitive function etc.
* Participation in another trial in the past three months.
Primary outcome measure(s)
Postoperative numerical rating scales (NRS) at rest — Up to 72 hours after operation Resting NRS pain scores at 2 h after surgery.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.